Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Covington
Baxter
AstraZeneca
QuintilesIMS
Chubb
Farmers Insurance
Moodys
McKinsey

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,789,379

« Back to Dashboard

Summary for Patent: 5,789,379
Title: Glucagon-like peptide-2 analogs
Abstract:Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
Inventor(s): Drucker; Daniel J. (Toronto, CA), Crivici; Anna E. (Toronto, CA), Sumner-Smith; Martin (Bolton, CA)
Assignee: Allelix Biopharmaceutical Inc. (Mississauga, CA) 1149336 Ontario Inc. (Toronto, CA)
Application Number:08/669,791
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 5,789,379

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Nps Pharms Inc GATTEX KIT teduglutide recombinant POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,789,379

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,846,625 Glucagon-like peptide-2 analogs ➤ Sign Up
6,184,201 Intestinotrophic glucagon-like peptide-2 analogs ➤ Sign Up
7,049,284 Glucagon-like peptide-2 and its therapeutic use ➤ Sign Up
5,834,428 Glucagon-like peptide-2 and its therapeutic use ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,789,379

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Spain 2334864 ➤ Sign Up
European Patent Office 2275438 ➤ Sign Up
European Patent Office 2218734 ➤ Sign Up
European Patent Office 2009024 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Deloitte
Cerilliant
Teva
Merck
Moodys
Queensland Health
Argus Health
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.